TickerFacts.

Ligand Pharmaceuticals Inc (LGND): Cost of Revenue

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest Cost of Revenue is for the year ended 2018-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$6.34M
Year ended 2018-12-31
+3.0%
3-year compound annual growth
+2.0%
5-year compound annual growth
$9.14M2011-12-31: $4.91M2012-12-31: $3.60M2013-12-31: $5.73M2014-12-31: $9.14M2015-12-31: $5.81M2016-12-31: $5.57M2017-12-31: $5.37M2018-12-31: $6.34M$6.34M
2011-12-31 Cost of Revenue (USD) 2018-12-31
Period endedCost of RevenueChange YoYSource filing
2018-12-31$6.34M+18.1%2019-02-28, From 2018-01-01
2017-12-31$5.37M-3.7%2019-02-28, From 2017-01-01
2016-12-31$5.57M-4.1%2019-02-28, From 2016-01-01
2015-12-31$5.81M-36.4%2018-03-01, From 2015-01-01
2014-12-31$9.14M+59.4%2017-02-28, From 2014-01-01
2013-12-31$5.73M+59.2%2016-11-14, From 2013-01-01
2012-12-31$3.60M-26.6%2015-02-23, From 2012-01-01
2011-12-31$4.91Mn/a2014-12-12, From 2011-01-01